Drug Profile
AZD 4818
Alternative Names: AZD4818Latest Information Update: 13 Oct 2009
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action CCR1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 16 Sep 2009 Pharmacodynamics data from a preclinical trial in Chronic obstructive pulmonary disease presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
- 16 Sep 2009 Efficacy and adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
- 29 Jan 2009 Discontinued - Phase-I for Chronic obstructive pulmonary disease in Japan (Inhalation)